

GOODWIN | PROCTER

RECEIVED
CENTRAL FAX CENTER

MAR 12 2007

Goodwin Procter LLP
Counselors at Law
599 Lexington Avenue
New York, NY 10022
T: 212.813.8800**F A X T R A N S M I T T A L**

If problems with transmittal, call fax department at 212.813.8800.

Date	Total pages	Attorney number	Client/matter number
March 12, 2007	13		

To	Company	Fax number	Telephone
Commissioner for Patents	USPTO	571.273.8300	

From	Fax number	Telephone
Robert P. Udal (Reg. No. 56,608)	212.355.3333	212.813.8840

Appl. No. : 10/608,520
 Applicant : Matthias Gerlach et al.
 Filed : June 27, 2003
 Title : Aryl-and Heteroarylcarbonylpiperazines and Their Use for the Treatment of Benign and Malignant Oncoses
 TC/A.U. : 1623
 Examiner : Paul V. Ward
 Atty. Docket No. : 103832-506-NP

Dear Sir or Madam:

Submitted herewith is the following item for filing in the above-captioned application.

- Reply to Restriction Requirement (12 pages).

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence, and attachments, if any, is being facsimile transmitted to the United States Patent and Trademark Office at fax number (571) 273-8300 on the date indicated below.

*Robert P. Udal**3/12/2007*

Robert P. Udal

Date

The information contained in this communication is intended only for the personal and confidential use of the designated recipients addressed. This message may be an attorney-client communication from an attorney at the law firm of Goodwin Procter LLP and as such is privileged and confidential. If the reader of this message is not the intended recipient, you are hereby notified that you have received this communication in error, and that any review, dissemination, distribution or copying of this message is strictly prohibited. If you have received this communication in error, please notify us at the telephone number shown above, and return the original message to us by mail. Thank you.

LIBNY/4586362.1

RECEIVED
CENTRAL FAX CENTER

MAR 12 2007

CERTIFICATE OF TRANSMISSION

I hereby certify that this correspondence, and attachments, if any, is being facsimile transmitted to the United States Patent and Trademark Office at fax number (571) 273-8300 on the date indicated below.

5

Robert P. Udall
Robert P. Udall3/12/2007
Date**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No. : 10/608,520
Applicant : Matthias Gerlach et al.
Filed : June 27, 2003
Title : Aryl- and Heteroarylcarbonylpiperazines and Their Use for the
Treatment of Benign and Malignant Oncoses
TC/A.U. : 1623
Examiner : Paul V. Ward
Atty. Docket No. : 103832-506-NP

10

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


REPLY TO OFFICE ACTION

15

Sir:

20

Responsive to the Restriction Requirement dated February 23, 2007, the claims of invention subgroup II_f (Claims 1-20) drawn to compounds and compositions according to Formula I, wherein n is 1 and R₁ is 1H-pyrazole are herein elected. Applicant further elects the compound [4-(3-methoxyphenyl)piperazin-1-yl]-(2-phenyl-2H-pyrazol-3-yl)methanone, a specifically disclosed species described on page 16 of the specification, see example 3 (compound No. 14), for prosecution on merits. The elected species has the following formula.



[4-(3-Methoxyphenyl)piperazin-1-yl]-(2-phenyl-2H-pyrazol-3-yl)methanone (14)

Applicant reserves the right to file a continuing application to protect the non-elected inventive
embodiments. Applicant does not hereby abandon or waive any rights in the non-elected
5 inventive embodiments. For completeness, this reply to the Restriction Requirement includes
not only the election subgroup II \bar{f} and a specifically disclosed species thereof, but also a listing
of all claims readable thereon. The listing of claims begins on page 3 of this paper. Remarks
begin on page 12 of this paper.

10

15

20